News & Events
-
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
-
September 8, 2022
C-Path’s Kristen Swingle Named President
Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path... - October 24, 2017
- April 18, 2017
-
April 11, 2017
PTC Meets Its Deliverables
April 11, 2017 Dear Colleagues, In the fall of 2015 C-Path established the Pediatric Trials Consortium (PTC), with the goal of supporting the formation of a new, independent nonprofit organization that would develop a network of clinical trial sites with the specific capability to conduct registration-quality clinical trials for new medical products for children....
